FDA warns stem cell company over unapproved treatments
The US Food and Drug Administration ( FDA) has sent a warning letter to a stem cell company for marketing a number of unapproved treatments for a variety of life-threatening conditions.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 April 2019 The US Food and Drug Administration and US Customs and Border Protection have strengthened their collaboration in a bid to halt the import of counterfeit drugs and protect public health.
11 March 2019 Pharmaceutical distributor CanaRx Services has hit back at criticism from the US Food and Drug Administration over the Canadian company’s alleged supply of unapproved and misbranded drugs.
5 April 2019 The US Food and Drug Administration and US Customs and Border Protection have strengthened their collaboration in a bid to halt the import of counterfeit drugs and protect public health.
11 March 2019 Pharmaceutical distributor CanaRx Services has hit back at criticism from the US Food and Drug Administration over the Canadian company’s alleged supply of unapproved and misbranded drugs.
5 April 2019 The US Food and Drug Administration and US Customs and Border Protection have strengthened their collaboration in a bid to halt the import of counterfeit drugs and protect public health.
11 March 2019 Pharmaceutical distributor CanaRx Services has hit back at criticism from the US Food and Drug Administration over the Canadian company’s alleged supply of unapproved and misbranded drugs.
